Laelaps Therapeutics’ mission is to develop therapeutic antibodies and proteins for the treatment of rare bleeding disorders including acquired Von Willebrand syndrome and haemophilia. The start-up has a pipeline of three molecules resulting from academic research, protected by a large patent portfolio.
